ZA964871B - Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures. - Google Patents

Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures.

Info

Publication number
ZA964871B
ZA964871B ZA9604871A ZA964871A ZA964871B ZA 964871 B ZA964871 B ZA 964871B ZA 9604871 A ZA9604871 A ZA 9604871A ZA 964871 A ZA964871 A ZA 964871A ZA 964871 B ZA964871 B ZA 964871B
Authority
ZA
South Africa
Prior art keywords
ferrites
conjugates
oligonucleotides
certain target
target structures
Prior art date
Application number
ZA9604871A
Other languages
English (en)
Inventor
Detlev Pfefferer
Johannes Platzek
Heinz Gries
Larry Gold
Mayk Kresse
Ulrich Niedballa
Bernd Raduechel
Original Assignee
Schering Ag
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Nexstar Pharmaceuticals Inc filed Critical Schering Ag
Publication of ZA964871B publication Critical patent/ZA964871B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA9604871A 1995-06-07 1996-06-07 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures. ZA964871B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47611695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ZA964871B true ZA964871B (en) 1997-02-06

Family

ID=23890573

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604871A ZA964871B (en) 1995-06-07 1996-06-07 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures.

Country Status (4)

Country Link
JP (1) JPH11507027A (xx)
AU (1) AU6222496A (xx)
WO (1) WO1996040273A2 (xx)
ZA (1) ZA964871B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100334228C (zh) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8507706D0 (en) * 1985-03-25 1985-05-01 Genetics Int Inc Magnetic nucleic acid sequences
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4847193A (en) * 1987-06-18 1989-07-11 Gene-Trak Systems Signal amplification in an assay employing a piezoelectric oscillator
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US5516670A (en) * 1991-09-30 1996-05-14 Kuehnle; Adelheid R. Magnetophoretic particle delivery method and apparatus for the treatment of cells
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
DE4424922A1 (de) * 1994-07-14 1996-01-18 Schering Ag Konjugate aus Metallkomplexen und Oligonucleotiden, die spezifisch an bestimmte Zielstrukturen binden
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same

Also Published As

Publication number Publication date
JPH11507027A (ja) 1999-06-22
WO1996040273A2 (en) 1996-12-19
WO1996040273A3 (en) 1997-03-27
AU6222496A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
ZA965190B (en) Pharmaceutical composition.
ZA982253B (en) Therapeutic compositions.
AU1462300A (en) Human pan-hcv human monoclonal antibodies
GB2328459B (en) Improved pulser
HUP0101155A3 (en) Imidazonaphthyridines, pharmaceutical compositions thereof and intermediates
ZA967034B (en) Pharmaceutical compositions.
NO980707D0 (no) Fremgangsmåte til fremstilling av kopolymerer
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
HK1030753A1 (en) Fracture healing using pthrp analogs.
BR9805993B1 (pt) composição farmacêutica de aerossol.
HK1027957A1 (en) Pharmaceutical composition.
IL117340A (en) Dual operating mode warhead
ZA9811504B (en) Novel pharmaceutical.
ZA989680B (en) Pharmaceutical composition.
AU3340797A (en) Modified oligonucleotides
ZA987913B (en) Fractionation of hemicellulosic materials.
ZA987392B (en) Pharmaceutical composition.
ZA964871B (en) Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures.
HK1027110A1 (en) Production of avermectin compounds.
ZA965111B (en) Fragmentation grenades
GB2325865B (en) Target construction
IL141523A0 (en) High-affinity antibodies
AU9321198A (en) Dosage forms having improved release properties
ZA982255B (en) Process for the preparation of arylmalonates.
MX194732B (es) Composicion de cemento.